Author

Gregory J. Opiteck 1

1 Gossamer Bio, Inc.,San Diego,United States

EFFICACY OF RPC4046, AN ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS: ANALYSIS OF THE STEROID-REFRACTORY SUBGROUP FROM THE HEROES STUDY

Evan S Dellon, Margaret H. Collins, Yehudith Assouline Dayan, Larry Evans, Sandeep Gupta, Alain Schoepfer, Alex Straumann, Ekaterina Safroneeva, Amy Woo, Gregory J. Opiteck, Allan Olson, Richard Aranda, Marc E. Rothenberg, Ikuo Hirano

GB004 EXHIBITS PROTECTIVE EFFECTS DIRECTLY ON EPITHELIAL CELLS USING EX VIVO ORGANOID AND MONOLAYER CULTURES

Kristen Taylor Meadows, Susan Murphy, Gregory J. Opiteck, Barrett G. Levesque, Laura Carter, Luisa Salter-CId

LONG-TERM EFFICACY AND SAFETY OF RPC4046, AN ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY, IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE OPEN-LABEL EXTENSION OF THE HEROES STUDY

Evan S Dellon, Margaret H. Collins, Yehudith Assouline Dayan, Larry Evans, Sandeep Gupta, Alain Schoepfer, Alex Straumann, Ekaterina Safroneeva, Amy Woo, Allan Olson, Gregory J. Opiteck, Richard Aranda, Ikuo Hirano

MARKERS OF ESOPHAGEAL EPITHELIAL-MESENCHYMAL TRANSITION ARE SIGNIFICANTLY REDUCED IN ACTIVE EOSINOPHILIC ESOPHAGITIS FOLLOWING 16 WEEKS OF TREATMENT WITH RPC4046, AN ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY

Peter Gann, Ryan Deaton, Nathan McMahon, Margaret H. Collins, Evan S Dellon, Ikuo Hirano, Michael Grimm, Amy Woo, Mahinda Karunaratne, Allan Olson, Richard Aranda, Gregory J. Opiteck

SAFETY, PHARMACOKINETIC, BIOMARKER, HISTOLOGIC, AND RECTAL BLEEDING ACTIVITY FOLLOWING TREATMENT WITH THE GUT-TARGETED, PHD-INHIBITOR AND HIF-1α STABILIZER GB004 IN A PHASE 1B TRIAL IN MILD-TO-MODERATE ULCERATIVE COLITIS

William Sandborn, Brian G. Feagan, Silvio Danese, Alina Jucov, B.R. Bhandari, Kartik Raghupathi, Allan Olson, Courtney Van Biene, Gregory J. Opiteck, Julia Ford, Richard Aranda, Barrett G. Levesque

Item 1 - 5 / 5
1